GLOBAL COMMUNITY - ONSET BLOODSTREAM INFECTIONS DIAGNOSIS MARKET SIZE (2023 - 2030)

The Global Community-Onset Bloodstream Infections Diagnosis Market was estimated to be worth USD 4.98 Billion in 2023 and is projected to reach a value of USD 7.19 Billion by 2030, growing at a fast compound annual growth rate (CAGR) of 4.7% during the forecast period 2023-2030.

The market for community-onset bloodstream infections diagnosis is a subset of the wider industry, thus the precise market size may be smaller. However, the market for diagnosing community-onset bloodstream infections is anticipated to rise in the next years due to the rising frequency of community-acquired illnesses and the rising demand for point-of-care testing. Bloodstream infections that develop outside of hospitals or other healthcare facilities are referred to as community-onset bloodstream infections. Since community-onset bloodstream infections can be caused by a wide range of pathogens, including bacteria, viruses, and fungi, the diagnosis market for this type of illness is rather diverse. In order to diagnose community-onset bloodstream infections, a variety of clinical assessments, laboratory tests, and imaging studies are frequently used. Blood culture tests, which entail cultivating blood samples to look for infectious organisms, are some of the frequently used diagnostic procedures for community-onset bloodstream infections. Additionally, polymerase chain reaction (PCR), serology, and imaging tests including MRI, CT scans, and ultrasounds may be performed.

Due to rising awareness of the value of prompt and accurate diagnosis as well as the increasing prevalence of infections brought on by antibiotic-resistant bacteria, the market for community-onset bloodstream infections diagnosis is anticipated to continue expanding. In the upcoming years, the market is anticipated to rise as a result of the creation of new diagnostic tools and products.

Global Community-Onset Bloodstream Infections Diagnosis Market Drivers:

The increase in the occurrence and acquisition of infections is leading to a greater demand for CO-BSIs globally:

• Globally, the prevalence of CO-BSIs has been rising, especially in low- and middle-income nations. The demand for CO-BSI diagnostics is being driven by this increase in incidence. The requirement for early diagnosis and prompt treatment is driving up demand for quick diagnostic tests for CO-BSIs. Rapid diagnostic procedures can support doctors in timely treatment choices that improve patient outcomes. More precise and trustworthy diagnostic tests for CO-BSIs have been developed as a result of technological developments in diagnostic procedures. These innovations involve molecular and immunological methods that can identify a variety of diseases.

Healthcare Expenditure, Advanced Technologies, and Growing Awareness Are the Main Drivers of CO-BSI Diagnostics Market Growth:

• The market for CO-BSI diagnostics is being driven by the rising cost of healthcare in both developed and developing nations. The market is expanding due to the availability of superior healthcare facilities and the implementation of cutting-edge technologies. The demand for CO-BSI diagnostics is being driven by public healthcare and professionals' increasing knowledge of CO-BSIs. People are more likely to seek out early diagnosis and treatment as a result of the informational accessibility regarding the dangers and effects of CO-BSIs.

Global Community-Onset Bloodstream Infections Diagnosis Market Challenges:

Numerous infections, such as bacteria, viruses, and fungi, can result in CO-BSI. Since symptoms of the infection may be vague and culture results may not be available for several days, determining its precise origin can be challenging. Symptoms of COBSI can resemble those of other illnesses, such as pneumonia or urinary tract infections. Because of this, it may be challenging to distinguish COBSI from other illnesses. Doctors may recommend broad-spectrum antibiotics as a precaution because the cause of COBSI may not be immediately obvious. This may result in overusing antibiotics, which could help bacteria become resistant to them. The availability of resources for diagnosing and treating COBSI may be constrained in some contexts, such as low- and middle-income nations.

Global Community-Onset Bloodstream Infections Diagnosis Market Opportunities:

The creation of novel diagnostic technologies represents a large business opportunity in the CO-BSIs diagnosis sector. Currently, cultivating blood samples in the lab, which might take several days to yield findings, is the norm for diagnosing CO-BSIs. A quicker and more precise diagnosis of CO-BSIs may be possible with the use of new technologies like matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and polymerase chain reaction (PCR). Companies that create these technologies could win a sizable portion of the CO-BSIs diagnosis market. New point-of-care (POC) diagnostic tests are being developed for the CO-BSIs diagnosis market. POC tests are made to give quick, on-site infection diagnoses, which can be very helpful in places like emergency rooms and intensive care units. Businesses that can create POC tests that are reliable, simple to use, and affordable could win a sizable portion of the CO-BSIs diagnosis market. The most efficient antibiotic to treat a particular bacterial infection is chosen using AST products. The creation of new AST products that can precisely and speedily select the most efficient antibiotic is essential given the rising prevalence of antibiotic resistance.

COVID-19 Impact on the Global Community-Onset Bloodstream Infections Diagnosis Market:

The community-onset bloodstream infections (CO-BSIs) diagnosis market, among other areas of the global healthcare sector, has been significantly impacted by the COVID-19 pandemic. Although the pandemic had no immediate influence on the market for CO-BSI diagnosis, its long-term repercussions are still not fully known. The COVID-19 pandemic has caused a shift in healthcare funding in order to combat the pandemic, according to the CO-BSIs diagnosis market. The treatment of COVID-19 patients has required many healthcare facilities to reallocate resources, which has reduced the diagnosis and treatment of other disorders, including CO-BSIs. The development and introduction of novel diagnostic methods and products in the market for CO-BSIs diagnosis have also been delayed as a result of this resource reallocation. Global supply chains have been disrupted by the COVID-19 pandemic, which has affected the market for CO-BSIs diagnostics. Global supply chains are a common method used by businesses in the CO-BSIs diagnosis sector to source raw materials and produce goods.

Global Community-Onset Bloodstream Infections Diagnosis Market Recent Developments:

• In March 2022, The US Food and Drug Administration (FDA) approved various businesses' quick diagnostic tests for CO-BSIs. For instance, Becton, Dickinson and Company's Veritor System for Rapid Detection of CO-BSIs, which yields results in around 15 minutes, obtained clearance. This innovation is anticipated to speed up patient access to the right care and enhance the diagnosis of CO-BSIs.

• In January 2022, a number of businesses in the CO-BSIs diagnosis market increased the scope of their product offerings. The VITEK MS Plus technology, for instance, was introduced by bioMérieux and allows for the quick identification of bacteria that cause CO-BSIs. The device is projected to increase the precision and speed of diagnosis because it can quickly identify more than 500 bacteria.

GLOBAL COMMUNITY - ONSET BLOODTSREAM INFECTIONS DIAGNOSIS MARKET REPORT COVERAGE:

Global Community-Onset Bloodstream Infections Diagnosis Market Segmentation:

Global Community-Onset Bloodstream Infections Diagnosis Market Segmentation: By Component

• Instruments

• Consumable

• Software

• Services

• Other Components

These diagnostic tools and equipment include molecular diagnostic tools, automated identification and susceptibility systems, and blood culture systems. The most frequently utilized tools in the diagnosis of CO-BSIs are blood culture methods. Consumables such as blood culture bottles, reagents, and assay kits are included in the category for consumables used in CO-BSI diagnosis. Blood culture bottles are in more demand as automated blood culture equipment becomes more widely used. Software for deciphering and analyzing diagnostic information. As the software can help to increase the accuracy and speed of diagnosis, it is becoming more and more usual to employ it in the diagnosis of CO-BSIs. Services include diagnostic instrument installation, maintenance, and repair, as well as training and educational services.

Global Community-Onset Bloodstream Infections Diagnosis Market Segmentation: By Application

• Bacterial

• Fungal

• Mycobacterial

The identification of bloodstream bacterial infections is the most typical cause of CO-BSIs. Blood culture systems, automated identification and susceptibility systems, or molecular diagnostic procedures are frequently used to diagnose bacteremia. Fungal infections in the bloodstream, which can happen in immunocompromised persons, are diagnosed as fungemia. Molecular diagnostic techniques or blood culture methods are frequently used in the diagnosis of fungemia. The other infections that can affect the bloodstream, like parasitic or viral diseases. Molecular diagnostic techniques are frequently used in the diagnosis of various infections.

Global Community-Onset Bloodstream Infections Diagnosis Market Segmentation: By End-User

• Hospitals

• Diagnostic Centers

• Research Institutes

• Others

Facilities where patients are treated for CO-BSIs, including hospitals, clinics, and other medical centers. As the major setting for infection diagnosis and treatment, hospitals make up the largest end-user segment in the CO-BSIs diagnosis market. Diagnostic Centers include diagnostic facilities and labs with expertise in the identification of CO-BSIs. These facilities frequently carry out diagnostic procedures using sophisticated tools and qualified employees. Research Institutes include academic institutions and research institutes that study the diagnosis and treatment of CO-BSIs. Patients may be given diagnostic services by these institutes as a part of their research endeavors.

Global Community-Onset Bloodstream Infections Diagnosis Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East and Africa

Due to the high prevalence of infections, established healthcare infrastructure, and widespread use of cutting-edge technologies, the North American market is anticipated to lead the CO-BSIs diagnosis market. Due to the rising frequency of infections and rising need for diagnostic tests, the European market is anticipated to be the second-largest market for CO-BSIs diagnosis. The market for CO-BSIs diagnostics is anticipated to expand at the fastest rate in the Asia Pacific region, due to rising infection rates, rising healthcare costs, and the establishment of cutting-edge healthcare infrastructure. Due to rising awareness of the importance of early infection identification and treatment, the Latin American market for CO-BSI diagnostics is predicted to expand quickly.

Global Community-Onset Bloodstream Infections Diagnosis Market Key Players:

1. BD (Becton, Dickinson and Company)

2. bioMérieux SA

3. Thermo Fisher Scientific Inc.

4. Roche Diagnostics International Ltd.

5. Abbott Laboratories

6. Siemens Healthineers AG

7. Bruker Corporation

8. Bio-Rad Laboratories, Inc.

9. Danaher Corporation

10. Luminex Corporation

11. Meridian Bioscience, Inc.

12. QIAGEN N.V.

13. T2 Biosystems, Inc.

14. Accelerate Diagnostics, Inc.

15. Nanosphere, Inc.